Evaluation of a hepatitis B vaccination program in Taiwan: Impact on hepatocellular carcinoma development

Future Oncology

Volumn 6, Issue 1, 2010, Pages 21-23

  Chemin, Isabelle ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

HBV vaccine; Hepatocellularcarcinoma; Risk factors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

CANCER REGISTRY; DRUG EFFICACY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; NOTE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; TAIWAN; VACCINATION;

EID: 75149170252     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.158     Document Type: Note

References (15)

1. Chang MH, You SL, Chen CJ et al.; Taiwan Hepatoma Study Group: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101(19), 1348-1355 (2009).
2. Chen HL, Chang MH, Ni YH et al.: Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276(11), 906-908 (1996).
3. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S: Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 337(8744), 747-750 (1991). ■ Deals with an important question about the protection induced by the hepatitis B virus (HBV) vaccine.
4. Jilg W, Schmidt M, Deinhardt F: Prolonged immunity after late booster doses of hepatitis B vaccine. J. Infect. Dis. 157(6), 1267-1269 (1988).
5. van der Sande MA, Waight PA, Mendy M et al.: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2(1), E753 (2007). ■ Discusses the need of a booster dose of HBV vaccine for young adults.
6. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A: Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-ana lysis. Vaccine (2009) (Epub ahead of print). ■■ Meta-analysis about the need of a booster dose for HBV protection
7. Lim SG, Mohammed R, Yuen MF, Kao JH: Prevention of hepatocellular carcinoma in hepatitis B virus infection. J. Gastroenterol. Hepatol. 24(8), 1352-1357 (2009).
8. Karthigesu VD, Allison LM, Ferguson M, Howard CR: A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg 'a' determinant. J. Med. Virol. 58(4), 346-352 (1999).
9. Mendy M, D'Mello F, Kanellos T, Oliver S, Whittle H, Howard CR: Envelope protein variability among HBV-Infected asymptomatic carriers and immunized children with breakthrough infections. J. Med. Virol. 80(9), 1537-1546 (2008).
10. Raimondo G, Allain JP, Brunetto MR et al.: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49(4), 652-657 (2008). ■ Consensus statement report about HBV occult infections
11. Mu SC, Lin YM, Jow GM, Chen BF: Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J. Hepatol. 50(2), 264-272 (2009).
12. Viviani S, Carrieri P, Bah E et al.; Gambia Hepatitis Intervention Study: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol. Biomarkers Prev. 17(11), 3216-3223 (2008). ■■ A synthesis of another 20 years experience of HBV vaccination in Africa.
13. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M: The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6(12), 991-1000 (2007).
14. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ, Wild CP: The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J. Gastroenterol. Hepatol. 17(Suppl.), S441-S448 (2002). ■ Discusses the possibility of intervention studies on hepatocellular carcinoma risk factors.
15. Hung HF, Chen TH: Probabilistic cost-effectiveness ana lysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e Antigen positive prevalence. Vaccine 27(48), 6770-6776 (2009).